245 related articles for article (PubMed ID: 2725061)
21. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
Moormeier JA; Ratain MJ; Westbrook CA; Vardiman JW; Daly KM; Golomb HM
J Natl Cancer Inst; 1989 Aug; 81(15):1172-4. PubMed ID: 2746669
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of complete remission in hairy cell leukemia patients treated with alpha-IFN.
Lauria F; Foà R; Raspadori D; Pileri S; Tassinari A; Buzzi M; Zaccaria A; Zinzani PL; Tura S
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():176-8. PubMed ID: 2785426
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
24. Treatment of hairy cell leukemia with increasing doses of recombinant alpha A interferon.
Holmes R; Schwarz MA; Whiteside MG; Firkin FC
Aust N Z J Med; 1988 Jun; 18(4):557-62. PubMed ID: 3196242
[TBL] [Abstract][Full Text] [Related]
25. [Low dosage long-term treatment with recombinant alpha interferon induces in hairy cell leukemia continuous complete remission].
Erlacher L; Gisslinger H; Chott A
Wien Klin Wochenschr; 1991; 103(19):588-90. PubMed ID: 1759461
[TBL] [Abstract][Full Text] [Related]
26. [Use of alpha-interferon in the treatment of patients with hairy cell leukemia].
Gotić M; Rolović Z; Vuković S; Elezović I; Tomić D
Srp Arh Celok Lek; 1990; 118(7-8):277-84. PubMed ID: 2097776
[TBL] [Abstract][Full Text] [Related]
27. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
[TBL] [Abstract][Full Text] [Related]
28. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
[TBL] [Abstract][Full Text] [Related]
29. Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.
Bardawil RG; Ratain MJ; Golomb HM; Bitter MA; Groves C; Vardiman JW
Leukemia; 1987 Apr; 1(4):340-3. PubMed ID: 3669760
[TBL] [Abstract][Full Text] [Related]
30. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
Ratain MJ; Golomb HM; Vardiman JW; Westbrook CA; Barker C; Hooberman A; Bitter MA; Daly K
J Clin Oncol; 1988 Nov; 6(11):1714-21. PubMed ID: 3054003
[TBL] [Abstract][Full Text] [Related]
31. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
[TBL] [Abstract][Full Text] [Related]
32. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
[TBL] [Abstract][Full Text] [Related]
34. [The therapeutic effect of interferon-alpha exemplified by hairy cell leukemia].
Schwarzmeier JD
Wien Med Wochenschr; 1993; 143(16-17):412-5. PubMed ID: 8273363
[TBL] [Abstract][Full Text] [Related]
35. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
[TBL] [Abstract][Full Text] [Related]
36. Alpha interferon production in patients with hairy cell leukemia: correlations with disease activity and remission status.
Lepe-Zuniga JL; Quesada JR; Baron S; Reuben J; Gutterman JU
Hematol Pathol; 1987; 1(3):157-65. PubMed ID: 3150846
[TBL] [Abstract][Full Text] [Related]
37. Reconstitution of endogenous interferon a by recombinant interferon in hairy cell leukemia.
Shehata M; Schwarzmeier JD; Nguyen ST; Hilgarth M; Berger R; Hubmann R; Kickmaier S; Decker T
Cancer Res; 2000 Oct; 60(19):5420-6. PubMed ID: 11034083
[TBL] [Abstract][Full Text] [Related]
38. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
Golomb HM; Jacobs A; Fefer A; Ozer H; Thompson J; Portlock C; Ratain M; Golde D; Vardiman J; Burke JS
J Clin Oncol; 1986 Jun; 4(6):900-5. PubMed ID: 3519880
[TBL] [Abstract][Full Text] [Related]
39. Hairy cell leukemia: a model for studying the B cell family of diseases.
Al-Katib A; Berman E; Black P; Koziner B
Semin Oncol; 1986 Dec; 13(4 Suppl 5):48-54. PubMed ID: 3492047
[TBL] [Abstract][Full Text] [Related]
40. The importance of patient monitoring in clinical cytokine trials: use of serum markers to define biologically active doses.
Huber C; Herold M
Cancer Surv; 1989; 8(4):809-15. PubMed ID: 2518331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
